Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia
Vladimir Ivanov, Su-Peng Yeh, Jiri Mayer, Lalit Saini, Ali Unal, Michael Boyiadzis, David M Hoffman, Kingston Kang, Sadiya N Addo, Wellington L Mendes, Amir T Fathi, Vladimir Ivanov, Su-Peng Yeh, Jiri Mayer, Lalit Saini, Ali Unal, Michael Boyiadzis, David M Hoffman, Kingston Kang, Sadiya N Addo, Wellington L Mendes, Amir T Fathi
Abstract
Prevention of relapse is a major therapeutic challenge and an unmet need for patients with acute myeloid leukemia (AML). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis in AML cells. When combined with azacitidine, it leads to prolonged overall survival and rapid, durable remissions in treatment-naive AML patients ineligible for intensive chemotherapy. VIALE-M is a randomized, double-blind, two-arm study to evaluate the safety and efficacy of venetoclax in combination with oral azacitidine (CC-486) as maintenance therapy in patients in complete remission with incomplete blood count recovery after intensive induction and consolidation therapies. The primary end point is relapse-free survival. Secondary outcomes include overall survival, minimal residual disease conversion and improvement in quality-of-life. Trial Registration Number: NCT04102020 (ClinicalTrials.gov).
Keywords: BCL-2 inhibitor; CC-486 (oral azacitidine); acute myeloid leukemia; first remission; maintenance therapy; minimal residual disease conversion; phase III; relapse-free survival; venetoclax.
Source: PubMed